{"id":"NCT03662789","sponsor":"Oslo University Hospital","briefTitle":"Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients","officialTitle":"Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-04-25","primaryCompletion":"2020-02-27","completion":"2020-02-27","firstPosted":"2018-09-07","resultsPosted":"2021-05-25","lastUpdate":"2021-05-25"},"enrollment":102,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Transplant Recipients"],"interventions":[{"type":"DRUG","name":"Iron Isomaltoside 1000","otherNames":["Monofer B03AC-"]},{"type":"OTHER","name":"Placebo: NaCl 0,9%","otherNames":[]}],"arms":[{"label":"Iron isomaltoside 1000","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Iron deficiency is prevalent in heart transplant recipients, and may be associated with reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous iron isomaltoside on exercise capacity, muscle strength, cognition and quality of life in iron-deficient heart transplant recipients","primaryOutcome":{"measure":"Peak Oxygen Consumption","timeFrame":"6 months after intervention","effectByArm":[{"arm":"Iron Isomaltoside 1000","deltaMin":23.9,"sd":6.6},{"arm":"Placebo","deltaMin":22,"sd":6.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":1,"countries":["Norway"]},"refs":{"pmids":["33612360"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":52},"commonTop":["Infection","Bleeding","Musculoskeletal pain","Gout","Generalized Rash"]}}